Article

Gene therapy progress and prospects: novel gene therapy approaches for AIDS.

Department of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA, USA.
Gene Therapy (Impact Factor: 4.2). 04/2005; 12(6):467-76. DOI: 10.1038/sj.gt.3302488
Source: PubMed

ABSTRACT Acquired immunodeficiency syndrome (AIDS), caused by human immunodeficiency virus (HIV), kills millions worldwide every year. Vaccines against HIV still seem a distant promise. Pharmaceutical treatments exist, but these are not always effective, and there is increasing prevalence of viral strains with multidrug resistance. Highly active antiretroviral therapy (HAART) consists of inhibitors of viral enzymes (reverse transcriptase (RT) and protease). Gene therapy, first introduced as intracellular immunization, may offer hopes for new treatments to be used alone, or in conjunction with, conventional small molecule drugs. Gene therapy approaches against HIV-1, including suicide genes, RNA-based technology, dominant negative viral proteins, intracellular antibodies, intrakines, and peptides, are the subject of this review.

0 Bookmarks
 · 
82 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Gene therapy is now a reality with a number of early phase clinical trials having been completed and several currently in progress. In spite of some early setbacks substantial progress has been made with treatment of several different diseases using a variety of delivery vectors and transgenes. Indeed for some diseases gene therapy is now the treatment of choice, in particular the inherited immune deficiencies. Treatment of ocular diseases and cancer are also showing great promise. Immune responses and insertional mutagenesis still pose problems but refinement of delivery systems and an increased understanding of oncogene activation should ensure that more successful protocols will emerge in the near future. Continuous progress suggests that a wider range of diseases can be treated with gene therapy in the future. Key Wordsgene therapy–neoplasm–clinical trial–immunology
    Clinical Oncology and Cancer Research 01/2011; 8(1):10-15.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this paper, a highly efficient gene transfer vector with hepatocyte-targeted function, galactosylated poly(L-succinimide)-g-polyethylenimine-g-lactobionic acid (PSI-g-PEI-g-LA), was synthesized by conjugating lactobionic acid (LA) to biodegradable cationic PSI-g-PEIpolymers. The physicochemical properties of PSI-g-PEI-g-LA including buffer capability, plasmidDNA (pDNA) binding ability, cytotoxicity, zeta potential and complex size were explored. Dynamic light scattering (DLS) reveals that PSI-g-PEI-g-LA can compactly condense pDNA into nano-sized particles with a hydrodynamic diameter of 95–175 nm. PSI-g-PEI-g-LA exhibits much higher cell-biocompatibility compared to PSI-g-PEI and PEI. The hepatocyte-targeted function was demonstrated by comparative studies on three polymeric vectors including PSI-g-PEI-g-LA, PSI-g-PEI and PEI25k. The transfection efficiency was evaluated in two different cell lines including asialoglyco proteinreceptor (ASGP-R) bearing HepG2 cells and ASGP-R-lacking HeLa cells. The in vitro transfection tests using different reporter genes indicate that PSI-g-PEI-g-LA displays higher transfection activity in HepG2 cells due to the specific interaction between LA segments and its ASGP-R on HepG2 cells compared with PSI-g-PEI and PEI. In contrast, the three polymers exhibit similar transfection activity in HeLa cells. PSI-g-PEI-g-LA displays better serum-tolerant transfection ability. Based on these analyses, PSI-g-PEI-g-LA was used as the vector to mediate the transfection of a tumor-suppressor gene p53. By means of western blotting analysis, flow cytometry and confocal laser scanning microscopy techniques, considerably high p53 gene expression and consequently strong p53-inducing apoptosis of HepG2 cells are distinctly observed.
    Journal of Materials Chemistry 03/2011; 21(11):3585-3596. · 6.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since the first generation of molecular machines including photoresponsive crown ethers and its analogues was reported by Shinkai etal., a huge number of molecular machines exhibiting dynamic chemical and physical functions have been designed and developed. On the other hand, non-viral vectors are desired to possess conflicting properties to associate with DNA until reaching the nucleus as their final destination and dissociate from DNA there. In other words, non-viral vectors should work as a sort of molecular machinery. To overcome this dilemma, recently, much attention is focused on the development of the intelligent vectors, also called as ‘stimuli responsive vectors’ working as molecular machines. In this review, stimulus responsive gene delivery systems in which some structural factors and/or physiological properties are regulated in response to extracellular signals such as redox, pH, ultrasound, light, temperature, etc. are introduced as a new generation of non-viral vectors. These extracellular signals such as ultrasound, light, and temperature can be potent stimuli capable of site-, timing-, and duration-specific gene expression.
    Journal of Inclusion Phenomena 07/2007; 58(3):205-219. · 1.43 Impact Factor

Preview

Download
0 Downloads
Available from